James D Chalmers

List of Publications by Year
in descending order

349 papers	17,666 citations	15001 68 h-index	21843 118 g-index
371 all docs	371 docs citations	371 times ranked	13558 citing authors

#	Article	IF	Citations
1	High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest, 2022, 161, 40-53.	0.4	8
2	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respiratory Medicine,the, 2022, 10, 298-306.	5.2	70
3	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	3.1	21
4	Treating Neutrophilic Inflammation in Airways Diseases. Archivos De Bronconeumologia, 2022, 58, 463-465.	0.4	18
5	Sputum Proteomics in Nontuberculous Mycobacterial Lung Disease. Chest, 2022, 161, 1180-1191.	0.4	8
6	Bronchiectasis and inhaled tobramycin: A literature review. Respiratory Medicine, 2022, 192, 106728.	1.3	11
7	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 2022, 2022, CD013254.	1.5	4
8	Just breathe: a review of sex and gender in chronic lung disease. European Respiratory Review, 2022, 31, 210111.	3.0	32
9	The evolution of the European Respiratory Journal: adapting in an era of change. European Respiratory Journal, 2022, 59, 2200037.	3.1	1
10	Critical appraisal of international adult bronchiectasis guidelines using the AGREE II tool. European Journal of Internal Medicine, 2022, , .	1.0	1
11	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902.	2.5	67
12	Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. European Respiratory Review, 2022, 31, 210241.	3.0	44
13	Bronchiectasis: Advances in Diagnosis and Management. Clinics in Chest Medicine, 2022, 43, xiii.	0.8	1
14	Bronchiectasis from 2012 to 2022. Clinics in Chest Medicine, 2022, 43, 1-6.	0.8	5
15	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax, 2022, 77, 717-720.	2.7	16
16	Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients. ERJ Open Research, 2022, 8, 00388-2021.	1.1	3
17	Bronchiectasis enters the inflammation era. Respirology, 2022, 27, 488-489.	1.3	3
18	Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the â€œChronic Obstructive Pulmonary Diseaseâ€“Bronchiectasis Associationâ€• American Journal of Respiratory and Critical Care Medicine, 2022, 206, 417-426.	2.5	29

#	Article	IF	Citations
19	Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. Annals of the American Thoracic Society, 2022, 19, 1489-1497.	1.5	3
20	Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study. European Respiratory Journal, 2022, 60, 2103168.	3.1	8
21	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	3.1	22
22	International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net. European Respiratory Journal, 2022, 59, 2200264.	3.1	8
23	World Bronchiectasis Day 2022. European Respiratory Journal, 2022, 59, 2201249.	3.1	3
24	Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clinical Infectious Diseases, 2021, 73, e256-e259.	2.9	16
25	The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2021, 147, 158-167.	1.5	102
26	A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 2021, 57, 2002050.	3.1	44
27	Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure. European Respiratory Journal, 2021, 57, 2003156.	3.1	14
28	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADOÂ® Trials. Advances in Therapy, 2021, 38, 579-593.	1.3	10
29	A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile. Chest, 2021, 159, 1758-1767.	0.4	18
30	Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. European Respiratory Journal, 2021, 57, 2001451.	3.1	30
31	Development of Drugs for Nontuberculous Mycobacterial Disease. Chest, 2021, 159, 537-543.	0.4	9
32	The evolution of the European Respiratory Journal: weathering the publishing pandemic. European Respiratory Journal, 2021, 57, 2100084.	3.1	3
33	Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism. European Respiratory Journal, 2021, 58, 2003157.	3.1	25
34	European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. European Respiratory Journal, 2021, 58, 2002990.	3.1	95
35	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Research, 2021, 7, 00775-2020.	1.1	4
36	Respiratory Mycoses in COPD and Bronchiectasis. Mycopathologia, 2021, 186, 623-638.	1.3	15

#	Article	IF	Citations
37	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	3.1	152
38	Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 2021, 27, 688-699.	15.2	105
39	Characteristics of bronchiectasis in Korea: First data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology, 2021, 26, 619-621.	1.3	30
40	The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. ERJ Open Research, 2021, 7, 00080-2021.	1.1	24
41	Pneumonia. Nature Reviews Disease Primers, 2021, 7, 25.	18.1	230
42	Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. European Respiratory Journal, 2021, 58, 2100025.	3.1	13
43	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Journal of Pragmatic and Observational Research, 2021, Volume 12, 25-35.	1.1	5
44	Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. ERJ Open Research, 2021, 7, 00122-2021.	1.1	28
45	The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort. European Respiratory Journal, 2021, 58, 2100360.	3.1	28
46	Patientsâ€™ perspectives on Bronchiectasis: findings from a social media listening (SML) study. ERJ Open Research, 2021, 7, 00096-2021.	1.1	6
47	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2021, 18, 1087-1097.	1.5	17
48	Bronchiectasis: Advances in Diagnosis and Treatment. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 497-498.	0.8	0
49	Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections. European Respiratory Review, 2021, 30, 210010.	3.0	16
50	The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 857-859.	2.5	33
51	Pathophysiology of Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 499-512.	0.8	17
52	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respiratory Medicine,the, 2021, 9, 1467-1478.	5.2	84
53	The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respiratory Medicine,the, 2021, 9, 885-896.	5.2	63
54	SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis. European Respiratory Journal, 2021, 58, 2101840.	3.1	3

#	Article	IF	Citations
55	Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial. ERJ Open Research, 2021, 7, 00253-2021.	1.1	4
56	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respiratory Medicine,the, 2021, 9, 873-884.	5.2	99
57	Inhaled Corticosteroids and the Lung Microbiome in COPD. Biomedicines, 2021, 9, 1312.	1.4	18
58	ROSE: radiology, obstruction, symptoms and exposure â€“ a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Research, 2021, 7, 00399-2021.	1.1	19
59	LTA4H rs2660845 association with montelukast response in early and late-onset asthma. PLoS ONE, 2021, 16, e0257396.	1.1	6
60	Associations between ambient air pollutants and hospital admissions: more needs to be done. Environmental Science and Pollution Research, 2021, 28, 61848-61852.	2.7	2
61	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	1.5	6
62	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1275-1287.	5.2	394
63	IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD. European Respiratory Journal, 2021, 58, 2102143.	3.1	1
64	What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Research, 2021, 7, 00807-2020.	1.1	8
65	The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102095.	1.1	41
66	An 18 year data-linkage study on the association between air pollution and acute limb ischaemia. Vasa - European Journal of Vascular Medicine, 2021, 50, 462-467.	0.6	1
67	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. European Respiratory Review, 2021, 30, 210171.	3.0	20
68	Precision medicine inÂbronchiectasis. Breathe, 2021, 17, 210119.	0.6	9
69	Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis. European Respiratory Journal, 2021, 58, 2101416.	3.1	2
70	Clinical trials during the COVID-19 pandemic: research design and lessons. , 2021, , 214-231.		0
71	Cystic fibrosis lung disease and bronchiectasis. Lancet Respiratory Medicine,the, 2020, 8, 12-14.	5.2	9
72	The microbiome in bronchiectasis: Cutting a lung story short. Respirology, 2020, 25, 43-44.	1.3	3

#	Article	IF	Citations
73	Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis. Chest, 2020, 157, 815-823.	0.4	25
74	Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 639-640.	2.5	4
75	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	3.0	82
76	Characteristics and outcomes of health and social care workers testing positive for SARS-CoV-2 in the Tayside region of Scotland. European Respiratory Journal, 2020, 56, 2002568.	3.1	9
77	Withdrawal of inhaled corticosteroids in COPD. European Respiratory Journal, 2020, 56, 2001778.	3.1	2
78	CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Research, 2020, 6, 00583-2020.	1.1	19
79	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 691.	0.7	62
80	A membrane-depolarizing toxin substrate of the Staphylococcus aureus type VII secretion system mediates intraspecies competition. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20836-20847.	3.3	57
81	Rewiring the Immune Response in COVID-19. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 784-786.	2.5	8
82	A cuckoo COVID coincidence?. European Respiratory Journal, 2020, 56, 2003236.	3.1	0
83	Drive-through testing for SARS-CoV-2 in symptomatic health and social care workers and household members: an observational cohort study. Thorax, 2020, 75, 1109-1111.	2.7	11
84	Using Airway Clearance Techniques in Bronchiectasis. Chest, 2020, 158, 1298-1300.	0.4	6
85	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respiratory Research, 2020, 21, 240.	1.4	29
86	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest, 2020, 158, 1912-1918.	0.4	26
87	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine, 2020, 383, 2127-2137.	13.9	158
88	European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights. ERJ Open Research, 2020, 6, 00317-2020.	1.1	9
89	Multiple breath washout in bronchiectasis clinical trials: is it feasible?. ERJ Open Research, 2020, 6, 00363-2019.	1.1	5
90	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal, 2020, 55, 2000351.	3.1	81

#	Article	IF	Citations
91	Estimates of the ongoing need for social distancing and control measures post-â€œlockdownâ€•from trajectories of COVID-19 cases and mortality. European Respiratory Journal, 2020, 56, 2001483.	3.1	53
92	Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 897-899.	2.5	14
93	The evolution of the European Respiratory Journal: ready for the new decade!. European Respiratory Journal, 2020, 55, 1902503.	3.1	0
94	Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis. European Respiratory Journal, 2020, 56, 2000769.	3.1	37
95	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.4	105
96	Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design. ERJ Open Research, 2020, 6, 00333-2019.	1.1	2
97	Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Journal, 2020, 56, 2000110.	3.1	30
98	Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With Bronchiectasis. Chest, 2020, 158, 512-522.	0.4	15
99	Managing and preventing exacerbation of bronchiectasis. Current Opinion in Infectious Diseases, 2020, 33, 189-196.	1.3	8
100	Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1499-1507.	2.5	25
101	Is bronchiectasis really a disease?. European Respiratory Review, 2020, 29, 190051.	3.0	10
102	Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. Respiratory Research, 2020, 21, 166.	1.4	44
103	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. European Respiratory Journal, 2020, 56, 2001702.	3.1	15
104	Counting the cost of bronchiectasis. Respirology, 2020, 25, 1223-1224.	1.3	5
105	Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST). Respiratory Research, 2020, 21, 18.	1.4	11
106	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.4	188
107	Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax, 2020, 75, 592-593.	2.7	19
108	Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies. European Respiratory Journal, 2020, 56, 2000608.	3.1	22

#	Article	IF	Citations
109	Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. BMJ Open Respiratory Research, 2020, 7, e000703.	1.2	12
110	Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD. European Respiratory Journal, 2020, 56, 2000391.	3.1	18
111	Pandemic trials: evidence-based medicine on steroids. European Respiratory Journal, 2020, 56, 2004116.	3.1	6
112	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK. PLoS Medicine, 2020, 17, e1003372.	3.9	3
113	Providing answers to respiratory patients' questions during COVID-19. Breathe, 2020, 16, 200219.	0.6	0
114	Providing answers to respiratory patients' questions during COVID-19. Breathe, 2020, 16, 200219.	0.6	1
115	Title is missing!. , 2020, 17, e1003372.		0
116	Title is missing!. , 2020, 17, e1003372.		0
117	Title is missing!. , 2020, 17, e1003372.		0
118	Title is missing!. , 2020, 17, e1003372.		0
119	Title is missing!. , 2020, 17, e1003372.		0
120	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	2.9	116
121	Treatment to prevent exacerbations in bronchiectasis: macrolides as first line?. European Respiratory Journal, 2019, 54, 1901213.	3.1	8
122	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	2.7	43
123	Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 992-1001.	2.5	42
124	Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101856.	1.1	16
125	Respiratory physiotherapy in the bronchiectasis guidelines: is there a loud voice we are yet to hear?. European Respiratory Journal, 2019, 54, 1901610.	3.1	23
126	Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 845-854.	5.2	104

#	Article	IF	Citations
127	Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology and Therapeutics, 2019, 58, 101834.	1.1	8
128	The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 855-869.	5.2	75
129	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	3.9	100
130	The evolution of theEuropean Respiratory Journal: volume 2. European Respiratory Journal, 2019, 53, 1802459.	3.1	0
131	Bronchiectasis Guidelines-Recommendations Into Practice. Archivos De Bronconeumologia, 2019, 55, 286-288.	0.4	1
132	Response. Chest, 2019, 155, 1302-1303.	0.4	0
133	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and riskÂofÂexacerbation. European Respiratory Journal, 2019, 53, 1900303.	3.1	50
134	Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 33-41.	2.5	70
135	Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial. BMC Pulmonary Medicine, 2019, 19, 85.	0.8	16
136	Rheumatoid arthritis-associated bronchiectasis â€“ Authors' reply. Lancet, The, 2019, 393, 2036.	6.3	3
137	Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?. F1000Research, 2019, 8, 293.	0.8	11
138	The economic burden of bronchiectasis â€“ known and unknown: a systematic review. BMC Pulmonary Medicine, 2019, 19, 54.	0.8	54
139	A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults. European Respiratory Review, 2019, 28, 180108.	3.0	21
140	Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. ERJ Open Research, 2019, 5, 00252-2018.	1.1	20
141	Reply: More on Causal Inference Studies. Annals of the American Thoracic Society, 2019, 16, 646-646.	1.5	0
142	Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration. ERJ Open Research, 2019, 5, 00113-2019.	1.1	4
143	British Thoracic Society Guideline for bronchiectasis in adults. Thorax, 2019, 74, 1-69.	2.7	291
144	The microbiome in bronchiectasis. European Respiratory Review, 2019, 28, 190048.	3.0	68

#	Article	IF	Citations
145	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	3.1	54
146	Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. Respiratory Research, 2019, 20, 242.	1.4	20
147	A 2 Ã— 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52â€‰weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. Trials, 2019, 20, 747.	0.7	7
148	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	1.5	458
149	Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respiratory Medicine,the, 2019, 7, 213-226.	5.2	134
150	Economic burden of bronchiectasis in Germany. European Respiratory Journal, 2019, 53, 1802033.	3.1	44
151	Distinct â€œImmunoallertypesâ€•of Disease and High Frequencies of Sensitization in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 842-853.	2.5	57
152	Bronchiectasis Guidelines-Recommendations Into Practice. Archivos De Bronconeumologia, 2019, 55, 286-288.	0.4	5
153	POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30%Ââ‰ÂFEV1Â< 50% Predicted) COPD? Yes. Chest, 2018, 153, 778-782.	0.4	7
154	Bronchiectasis: new therapies and new perspectives. Lancet Respiratory Medicine,the, 2018, 6, 715-726.	5.2	147
155	Rebuttal From Dr Chalmers. Chest, 2018, 153, 785-786.	0.4	0
156	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. Respiratory Medicine, 2018, 137, 6-13.	1.3	90
157	Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis. Respiratory Medicine, 2018, 136, 111-117.	1.3	21
158	RESPIRE: breathing new life into bronchiectasis. European Respiratory Journal, 2018, 51, 1702444.	3.1	46
159	Turning thirty: evolution but not revolution at the ERJ. European Respiratory Journal, 2018, 51, 1702594.	3.1	0
160	The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	3.1	150
161	Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. European Respiratory Journal, 2018, 51, 1701937.	3.1	23
162	Characterization of the â€œFrequent Exacerbator Phenotypeâ€•in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	2.5	215

#	Article	IF	Citations
163	The BRICS (Bronchiectasis Radiologically Indexed CT Score). Chest, 2018, 153, 1177-1186.	0.4	44
164	Macrolides, mucoactive drugs and adherence for the management of bronchiectasis. European Respiratory Journal, 2018, 51, 1702033.	3.1	7
165	Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respiratory Research, 2018, 19, 63.	1.4	22
166	Oral versus inhaled antibiotics for bronchiectasis. The Cochrane Library, 2018, 3, CD012579.	1.5	11
167	Macrolide antibiotics for bronchiectasis. The Cochrane Library, 2018, 2018, CD012406.	1.5	52
168	The Elusive Hunt for a Reliable Biomarker in Community-acquired Pneumonia. Are We Searching for Something That Canâ€™t Exist?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 300-302.	2.5	2
169	Bronchiectasis Exacerbations Are Heart-Breaking. Annals of the American Thoracic Society, 2018, 15, 301-303.	1.5	7
170	Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 117-127.	1.5	207
171	Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD. Thorax, 2018, 73, 510-518.	2.7	28
172	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	0.6	1
173	Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial. ERJ Open Research, 2018, 4, 00136-2018.	1.1	0
174	Bronchiectasis. Nature Reviews Disease Primers, 2018, 4, 45.	18.1	181
175	A comprehensive approach to lung function in bronchiectasis. Respiratory Medicine, 2018, 145, 120-129.	1.3	46
176	The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respiratory Research, 2018, 19, 249.	1.4	10
177	British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research, 2018, 5, e000348.	1.2	37
178	New Insights Into the Epidemiology of Bronchiectasis. Chest, 2018, 154, 1272-1273.	0.4	17
179	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. European Respiratory Journal, 2018, 52, 1802074.	3.1	26
180	A systematic review of clinical trial registration in major respiratory journals 2010â€“2018. European Respiratory Journal, 2018, 52, 1801491.	3.1	1

#	Article	IF	Citations
181	How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis. International Journal of Molecular Sciences, 2018, 19, 3256.	1.8	28
182	Get together to increase awareness in bronchiectasis: a report of the 2nd World Bronchiectasis Conference. Multidisciplinary Respiratory Medicine, 2018, 13, 28.	0.6	4
183	Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet, The, 2018, 392, 880-890.	6.3	247
184	Treatable traits in bronchiectasis. European Respiratory Journal, 2018, 52, 1801269.	3.1	84
185	â€œThe missing ingredientâ€• the patient perspective of health related quality of life in bronchiectasis: a qualitative study. BMC Pulmonary Medicine, 2018, 18, 81.	0.8	28
186	Predicting outcomes in bronchiectasis. Pulmonology, 2018, 24, 146-148.	1.0	3
187	Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulmonary Medicine, 2018, 18, 83.	0.8	143
188	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. European Respiratory Journal, 2018, 52, 1800328.	3.1	138
189	Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. European Respiratory Journal, 2018, 52, 1701190.	3.1	122
190	Bronchiectasis: an emerging global epidemic. BMC Pulmonary Medicine, 2018, 18, 76.	0.8	30
191	Bronchiectasis: a case-based approach to investigation and management. European Respiratory Review, 2018, 27, 180016.	3.0	26
192	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	0.6	10
193	Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 2018, 13, 26.	0.6	27
194	Continuous versus intermittent antibiotics for bronchiectasis. The Cochrane Library, 2018, 2018, CD012733.	1.5	8
195	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respiratory Medicine, 2018, 140, 115-121.	1.3	11
196	Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. European Respiratory Journal, 2018, 52, 1800766.	3.1	105
197	The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. European Respiratory Journal, 2018, 52, 1702557.	3.1	42
198	Severe Paediatric Asthma Collaborative in Europe (SPACE): protocol for a European registry. Breathe, 2018, 14, 93-98.	0.6	10

#	Article	IF	Citations
199	The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry. , 2018, , .		4
200	What is the best technique to extract bacterial DNA from sputum?. , 2018, , .		1
201	Additional important research priorities for bronchiectasis in China. European Respiratory Journal, 2017, 49, 1602317.	3.1	0
202	Disbiosis microbiana en las bronquiectasias y la fibrosis quÃstica. Archivos De Bronconeumologia, 2017, 53, 471-472.	0.4	1
203	Oral versus inhaled antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2017, , .	1.5	1
204	Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For. Respiration, 2017, 93, 228-229.	1.2	10
205	Year in review 2016: Respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology. Respirology, 2017, 22, 602-611.	1.3	7
206	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent RiskÂFactor for Mortality in Patients WithÂBronchiectasis. Chest, 2017, 151, 1247-1254.	0.4	81
207	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
208	Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. Respiratory Medicine, 2017, 128, 1-6.	1.3	18
209	The heterogeneity of systemic inflammation in bronchiectasis. Respiratory Medicine, 2017, 127, 33-39.	1.3	58
210	Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1384-1393.	2.5	232
211	Bronchiectasis and COPD Overlap. Chest, 2017, 151, 1204-1206.	0.4	17
212	Macrolide resistance in Pseudomonas aeruginosa: implications for practice. European Respiratory Journal, 2017, 49, 1700689.	3.1	11
213	A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa. Chest, 2017, 152, 368-378.	0.4	31
214	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	3.1	253
215	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 609-620.	2.5	120
216	Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis. Archivos De Bronconeumologia, 2017, 53, 471-472.	0.4	1

#	Article	IF	Citations
217	New therapies for the prevention and treatment of exacerbations of bronchiectasis. Current Opinion in Pulmonary Medicine, 2017, 23, 218-224.	1.2	8
218	Management of chronic airway diseases: What can we learn from real-life data?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, S1-S2.	0.7	2
219	Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study. Pneumonia (Nathan Qld), 2017, 9, 2.	2.5	2
220	Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. Npj Primary Care Respiratory Medicine, 2017, 27, 18.	1.1	32
221	Bronchiectasis: Phenotyping a Complex Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, S12-S18.	0.7	26
222	Patient participation in ERS guidelines and research projects: the EMBARC experience. Breathe, 2017, 13, 194-207.	0.6	20
223	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. European Respiratory Journal, 2017, 50, 1602306.	3.1	5
224	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	3.1	788
225	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. Breathe, 2017, 13, 180-192.	0.6	34
226	Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. Expert Review of Molecular Diagnostics, 2017, 17, 875-884.	1.5	10
227	10â€...years since TORCH: shining a new light on the risks of inhaled corticosteroids in COPD. European Respiratory Journal, 2017, 50, 1701582.	3.1	9
228	Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2017, , .	1.5	2
229	Bronchiectasis Management. Chest, 2017, 152, 1097-1099.	0.4	3
230	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	3.1	63
231	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	3.1	9
232	The past decade in bench research into pulmonary infectious diseases: <scp>W</scp>hat do clinicians need to know?. Respirology, 2017, 22, 1062-1072.	1.3	9
233	Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. Npj Primary Care Respiratory Medicine, 2017, 27, 43.	1.1	53
234	The type VII secretion system of Staphylococcus aureus secretes a nuclease toxin that targets competitor bacteria. Nature Microbiology, 2017, 2, 16183.	5.9	206

#	Article	IF	Citations
235	Role of cephalosporins in the era ofClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2017, 72, 1-18.	1.3	60
236	Withdrawal of ICS treatment in primary care: A practical guide. Practice Nursing, 2017, 28, 22-27.	0.1	4
237	Community-acquired pneumonia in the United Kingdom: a call to action. Pneumonia (Nathan Qld), 2017, 9, 15.	2.5	48
238	Phenotype characterization of non-cystic fibrosis bronchiectasis in India. , 2017, , .		1
239	Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study.. The University of Louisville Journal of Respiratory Infections, 2017, 1, 3-11.	0.2	13
240	Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. International Journal of Molecular Sciences, 2016, 17, 1913.	1.8	70
241	<scp>Pseudomonas aeruginosa</scp> resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology, 2016, 21, 1235-1242.	1.3	33
242	Quality standards for the management of bronchiectasis in Italy: a national audit. European Respiratory Journal, 2016, 48, 244-248.	3.1	33
243	Microbial Dysbiosis after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1184-1186.	2.5	5
244	Reply: Measuring Airway Mucin 2 in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 2104-2105.	1.5	1
245	The Modern Diagnostic Approach to Community-Acquired Pneumonia in Adults. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 876-885.	0.8	10
246	Community-Acquired Pneumonia: A Global Perspective. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 797-798.	0.8	3
247	Cardiovascular disease as a complication of community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2016, 22, 212-218.	1.2	56
248	Diagnostic challenges of bronchiectasis. Respiratory Medicine, 2016, 116, 70-77.	1.3	27
249	Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. Journal of Infection, 2016, 73, 45-53.	1.7	60
250	Clinical phenotypes in bronchiectasis: right on track to develop precision medicine in respiratory diseases. International Journal of Tuberculosis and Lung Disease, 2016, 20, 709-709.	0.6	1
251	A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulmonary Medicine, 2016, 16, 77.	0.8	62
252	Global impact of bronchiectasis and cystic fibrosis. Breathe, 2016, 12, 222-235.	0.6	51

#	Article	IF	Citations
253	Corticosteroids for community-acquired pneumonia: a critical view of the evidence. European Respiratory Journal, 2016, 48, 984-986.	3.1	20
254	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	1.4	54
255	Characterization of bronchiectasis in the elderly. Respiratory Medicine, 2016, 119, 13-19.	1.3	28
256	Empirical Coverage of Methicillin-ResistantStaphylococcus aureusin Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It. Clinical Infectious Diseases, 2016, 63, 1145-1146.	2.9	12
257	Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respiratory Medicine,the, 2016, 4, 969-979.	5.2	210
258	Macrolide antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2016, , .	1.5	5
259	Community-acquired pneumonia related to intracellular pathogens. Intensive Care Medicine, 2016, 42, 1374-1386.	3.9	85
260	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal, 2016, 48, 632-647.	3.1	170
261	Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 636-642.	1.5	19
262	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. Respiratory Medicine, 2016, 112, 51-58.	1.3	27
263	Clinical phenotypes in adult patients with bronchiectasis. European Respiratory Journal, 2016, 47, 1113-1122.	3.1	215
264	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	1.1	133
265	Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC). , 2016, , .		2
266	Multidimensional severity assessment in bronchiectasis - An analysis of 7 European cohorts. , 2016, , .		1
267	Middle East Respiratory Syndrome. Critical Care Medicine, 2015, 43, 1344-1346.	0.4	2
268	Empirical Antibiotic Treatment for Community-acquired Pneumonia. Clinical Pulmonary Medicine, 2015, 22, 192-198.	0.3	0
269	Identifying severe community-acquired pneumonia: moving beyond mortality. Thorax, 2015, 70, 515-516.	2.7	11
270	No Strong Relationship Between Components of the Lectin Pathway of Complement and Susceptibility to Pulmonary Tuberculosis. Inflammation, 2015, 38, 1731-1737.	1.7	20

#	Article	IF	Citations
271	Reclaiming the name â€˜bronchiectasisâ€™. Thorax, 2015, 70, 399-400.	2.7	28
272	Secreted mucins and airway bacterial colonization in nonâ€‹<scp>CF</scp> bronchiectasis. Respirology, 2015, 20, 1082-1088.	1.3	43
273	Doing science: how to get credit for your scientific work. Breathe, 2015, 11, 153-155.	0.6	1
274	Bronchiectasis: working together for better evidence. Lancet Respiratory Medicine,the, 2015, 3, 915-917.	5.2	0
275	Old Drugs for Bad Bugsâ€”Aerosolized Antibiotics in Ventilator-Associated Pneumonia*. Critical Care Medicine, 2015, 43, 697-698.	0.4	2
276	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respiratory Medicine, 2015, 109, 743-750.	1.3	29
277	Management of bronchiectasis in adults. European Respiratory Journal, 2015, 45, 1446-1462.	3.1	220
278	Renal replacement therapy in Scottish critical care units: A national audit of practices. Journal of the Intensive Care Society, 2015, 16, 45-51.	1.1	1
279	Challenges in the development of new therapies for bronchiectasis. Expert Opinion on Pharmacotherapy, 2015, 16, 833-850.	0.9	20
280	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	0.9	8
281	Etiology of Nonâ€“Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society, 2015, 12, 1764-1770.	1.5	233
282	A Comprehensive Analysis of the Impact ofPseudomonas aeruginosaColonisation on Prognosis in Adult Bronchiectasis. Annals of the American Thoracic Society, 2015, 12, 1602-11.	1.5	258
283	Bronchiectasis in adults: epidemiology, assessment of severity and prognosis. Current Pulmonology Reports, 2015, 4, 142-151.	0.5	1
284	Community-acquired severity predictionâ€”what are we predicting and why?. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 173-174.	0.2	1
285	Defining severity in non-cystic fibrosis bronchiectasis. Expert Review of Respiratory Medicine, 2014, 8, 249-262.	1.0	16
286	Critical Care Transition and Prevention of ICU Readmissions. Critical Care Medicine, 2014, 42, 216-217.	0.4	1
287	Macrolides and Mortality in Severe Community-Acquired Pneumonia*. Critical Care Medicine, 2014, 42, 475-477.	0.4	0
288	Preventing Arterial Catheter-Associated Bloodstream Infections. Critical Care Medicine, 2014, 42, 1533-1534.	0.4	0

#	Article	IF	Citations
289	Sputum colour in nonâ€<scp>CF</scp> bronchiectasis: The original neutrophil biomarker. Respirology, 2014, 19, 153-154.	1.3	9
290	Heterogeneity in <scp>ess</scp> transcriptional organization and variable contribution of the <scp>Ess</scp>/Type <scp>VII</scp> protein secretion system to virulence across closely related <scp>S</scp>taphylocccus aureus strains. Molecular Microbiology, 2014, 93, 928-943.	1.2	84
291	The role of neutrophils in cystic fibrosis. Current Opinion in Hematology, 2014, 21, 16-22.	1.2	76
292	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory Research, 2014, 15, 27.	1.4	39
293	Reply to Corrao et al. Clinical Infectious Diseases, 2014, 58, 1197-1198.	2.9	1
294	Review of the British Thoracic Society Winter Meeting 2013, 4â€“6 December, London, UK. Thorax, 2014, 69, 378-382.	2.7	1
295	Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. European Respiratory Journal, 2014, 43, 842-851.	3.1	63
296	Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2014, 58, 330-339.	2.9	224
297	COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 603-604.	0.7	40
298	Bronchiectasis trials: losing the battle but winning the war?. Lancet Respiratory Medicine,the, 2014, 2, 679-681.	5.2	4
299	Reply to Livorsi and Eckerle. Clinical Infectious Diseases, 2014, 59, 610-611.	2.9	1
300	A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. Journal of Antimicrobial Chemotherapy, 2014, 69, 515-518.	1.3	34
301	Serum Ficolin-2 in Hospitalised Patients with Community-Acquired Pneumonia. Inflammation, 2014, 37, 1635-1641.	1.7	8
302	The Bronchiectasis Severity Index. An International Derivation and Validation Study. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 576-585.	2.5	747
303	Parapneumonic effusions: epidemiology and predictors of pleural infection. Current Respiratory Care Reports, 2014, 3, 52-60.	0.6	4
304	Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?. Thorax, 2014, 69, 609-615.	2.7	99
305	Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 455-463.	5.2	74
306	A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis. Npj Primary Care Respiratory Medicine, 2014, 24, 14090.	1.1	21

#	Article	IF	Citations
307	Severity assessment tools in CAP. , 2014, , 88-104.		3
308	Epidemiology of CAP in Europe. , 2014, , 1-12.		6
309	The Role of Bacteria and Viruses in Chronic Obstructive Pulmonary Disease. Current Respiratory Medicine Reviews, 2014, 9, 360-371.	0.1	2
310	Risk Factors for Aspiration in Community-acquired Pneumonia: Analysis of a Hospitalized UK Cohort. American Journal of Medicine, 2013, 126, 995-1001.	0.6	95
311	Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Molecular Immunology, 2013, 55, 27-34.	1.0	149
312	Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respiratory Medicine,the, 2013, 1, 224-232.	5.2	75
313	Predictors of Mortality in Hospitalized Adults with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2013, 10, 81-89.	1.5	203
314	Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respiratory Medicine,the, 2013, 1, 653-662.	5.2	29
315	Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax, 2013, 68, 39-47.	2.7	121
316	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: TableÂ1. Thorax, 2013, 68, 997-999.	2.7	129
317	Author responseâ€"vitamin D deficiency and systemic inflammation in bronchiectasis. Thorax, 2013, 68, 679.2-679.	2.7	1
318	Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ, The, 2013, 346, f1235-f1235.	3.0	101
319	Obesity is associated with improved survival in community-acquired pneumonia. European Respiratory Journal, 2013, 42, 180-187.	3.1	65
320	Human L-Ficolin (Ficolin-2) and Its Clinical Significance. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	77
321	Can we use severity assessment tools to increase outpatient management of community-acquired pneumonia?. European Journal of Internal Medicine, 2012, 23, 398-406.	1.0	21
322	Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Nonâ€"Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 657-665.	2.5	330
323	Factors associated with severe illness in pandemic 2009 influenza a (H1N1) infection: Implications for triage in primary and secondary care. Journal of Infection, 2011, 63, 243-251.	1.7	28
324	Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Medicine, 2011, 37, 1409-1420.	3.9	134

#	Article	IF	Citations
325	Investigation of "non-responding" presumed lower respiratory tract infection in primary care. BMJ: British Medical Journal, 2011, 343, d5840-d5840.	2.4	7
326	A Randomized Controlled Trial of Nebulized Gentamicin in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 491-499.	2.5	264
327	Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis. Glycobiology, 2011, 21, 271-282.	1.3	69
328	Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 416-423.	1.3	45
329	Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study. Clinical Infectious Diseases, 2011, 53, 107-113.	2.9	231
330	Validation of the Infectious Diseases Society of America/American Thoratic Society Minor Criteria for Intensive Care Unit Admission in Community-Acquired Pneumonia Patients Without Major Criteria or Contraindications to Intensive Care Unit Care. Clinical Infectious Diseases, 2011, 53, 503-511.	2.9	131
331	Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. Journal of Antimicrobial Chemotherapy, 2010, 65, 608-618.	1.3	51
332	Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax, 2010, 65, 878-883.	2.7	262
333	Incidence and Prognostic Implications of Acute Kidney Injury on Admission in Patients With Community-Acquired Pneumonia. Chest, 2010, 138, 825-832.	0.4	65
334	Right ventricular dilation on CT pulmonary angiogram independently predicts mortality in pulmonary embolism. Respiratory Medicine, 2010, 104, 1057-1062.	1.3	23
335	Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respiratory Medicine, 2010, 104, 1081-1091.	1.3	69
336	Admission D-dimer Can Identify Low-Risk Patients With Community-Acquired Pneumonia. Annals of Emergency Medicine, 2009, 53, 633-638.	0.3	57
337	ICU admission and severity assessment in community-acquired pneumonia. Critical Care, 2009, 13, 156.	2.5	33
338	Budesonide and risk of pneumonia. Lancet, The, 2009, 374, 2050.	6.3	4
339	C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired Pneumonia. American Journal of Medicine, 2008, 121, 219-225.	0.6	303
340	Prior Statin Use Is Associated with Improved Outcomes in Community-acquired Pneumonia. American Journal of Medicine, 2008, 121, 1002-1007.e1.	0.6	159
341	Predicting the Need for Mechanical Ventilation and/or Inotropic Support for Young Adults Admitted to the Hospital with Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 1571-1574.	2.9	67
342	A Powerful New Severity Score for Communityâ€Acquired Pneumonia But Will Anyone Use It?. Clinical Infectious Diseases, 2008, 47, 1363-1363.	2.9	3

#	Article	IF	Citations
343	Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 2495-2501.	1.3	35
344	Phenotypes and endotypes. , 0, , 133-152.		1
345	Neutrophil Extracellular Traps are Increased in Severe Bronchiectasis and Reduced by Long-Term Azithromycin Treatment. SSRN Electronic Journal, 0, , .	0.4	2
346	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 0, , .	1.5	1
347	Inhaled antibiotics in chronic airway infections. , 0, , 57-79.		0
348	Non-cystic fibrosis bronchiectasis: definition, severity and impact of pulmonary exacerbations. , 0, , 38-57.		0
349	Antibiotic stewardship in the hospital setting. , 0, , 127-149.		0